Global Gelatin Peptide Plasma Substitute Market Size, Share and Trend Analysis, By Type (Urea Bridged Gelatin Polypeptide, Succinic Acid Gelatin Polypeptide, and Poly Gelatin Peptide), By Application (Hospital and Clinic)

The global gelatin peptide plasma substitute market is anticipated to grow at a significant CAGR during the forecast period (2022- 2028).  Plasma substitutes are colloidal solutions that contain particles of such a molecular size that they stay in the intravascular space for a useful period of time. They are a newer class of products that have been developed to address some of the limitations of traditional plasma volume expanders. Gelatin peptides are small proteins derived from animal-sourced gelatin. They offer several potential advantages over other types of plasma expanders, including faster onset and offset of action, decreased incidence of allergic reactions, and lack of viral transmission risk. The increasing number of trauma cases and surgeries are one of the factors that are driving the growth of the market.

The market is segmented based on the type and application. Based on the type the market is sub-segmented into urea bridged gelatin polypeptide, succinic acid gelatin polypeptide, and poly gelatin peptide. Urea bridged gelatin polypeptide is a type of gelatin peptide plasma substitute. It is a white to off-white colored powder. Unabridged gelatin polypeptide is insoluble in water. It is derived from the hydrolysis of porcine or bovine skin and bone collagens. Urea bridged gelatin polypeptides are used as plasma substitutes in hospital settings. Succinic acid gelatin polypeptide (SAGP) is a novel, safe and effective plasma substitute. SAP is made up of two key ingredients, such as succinic acid and gelatin peptides. Succinic acid is a naturally occurring dicarboxylic acid that is produced in small amounts by the body. It plays an important role in the Krebs cycle, which is responsible for energy production in cells. Poly gelatin peptide is a novel, non-immunogenic, plasma substitute that has the potential to be used for a variety of indications requiring fluid resuscitation or replacement. It is made up of short chains of amino acids (peptides) that are linked together by chemical bonds. These bonds make the peptides resistant to digestion by enzymes, making poly gelatin peptide an ideal candidate for intravenous administration.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By  Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Braun Melsungen AG, and CSL Behring LLC, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Gelatin Peptide Plasma Substitute Report by Segment

By Type

• Urea Bridged Gelatin Polypeptide
• Succinic Acid Gelatin Polypeptide
• Poly Gelatin Peptide

By Application

• Hospital
• Clinic

Global Gelatin Peptide Plasma Substitute Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa